Cargando…

Differential expression of CD10 in prostate cancer and its clinical implication

BACKGROUND: CD10 is a transmembrane metallo-endopeptidase that cleaves and inactivates a variety of peptide growth factors. Loss of CD10 expression is a common, early event in human prostate cancer; however, CD10 positive cancer cells frequently appear in lymph node metastasis. We hypothesize that p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dall'Era, Marc A, True, Lawrence D, Siegel, Andrew F, Porter, Michael P, Sherertz, Tracy M, Liu, Alvin Y
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1829163/ https://www.ncbi.nlm.nih.gov/pubmed/17335564 http://dx.doi.org/10.1186/1471-2490-7-3

Ejemplares similares

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer
por: Glass, Allison S., et al.
Publicado: (2018)

Active Surveillance for Localized Prostate Cancer – Current Practices and Recommendations
por: Wu, Jennifer N., et al.
Publicado: (2010)

Active surveillance for prostate cancer
por: Dall’Era, Marc A., et al.
Publicado: (2018)

Defining the Optimal Management Strategy for Small Renal Masses
por: Dall’Era, Marc, et al.
Publicado: (2021)

Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis
por: Yazdany, Jinoos, et al.
Publicado: (2014)

Prostate cancer cell phenotypes based on AGR2 and CD10 expression
por: Ho, Melissa E., et al.
Publicado: (2013)

Differential Inductive Signaling of CD90(+) Prostate Cancer-Associated Fibroblasts Compared to Normal Tissue Stromal Mesenchyme Cells
por: Pascal, Laura E., et al.
Publicado: (2011)

Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
por: Dall'Era, Maria, et al.
Publicado: (2015)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Parikh, Mamta, et al.
Publicado: (2021)

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer()
por: Lombard, Alan P, et al.
Publicado: (2019)

Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry
por: Rector, Ian, et al.
Publicado: (2023)

Preliminary population-based incidence and prevalence estimates of systemic lupus erythematosus: the California Lupus Surveillance Project
por: Dall'Era, Maria C, et al.
Publicado: (2014)

Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
por: Kim, Isaac E., et al.
Publicado: (2021)

Validation study of a computer-based open surgical trainer: SimPraxis(®) simulation platform
por: Tran, Linh N, et al.
Publicado: (2013)

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype
por: Monda, Steven M., et al.
Publicado: (2023)

Transcriptomes of human prostate cells
por: Oudes, Asa J, et al.
Publicado: (2006)

Gene expression down-regulation in CD90(+ )prostate tumor-associated stromal cells involves potential organ-specific genes
por: Pascal, Laura E, et al.
Publicado: (2009)

Long-Term Disease Control with Triapine-Based Radiochemotherapy for Patients with Stage IB2–IIIB Cervical Cancer
por: Kunos, Charles A., et al.
Publicado: (2014)

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial
por: Tamirou, Farah, et al.
Publicado: (2015)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
por: Collins, C E, et al.
Publicado: (2016)

Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient‐Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus
por: Katz, Patricia, et al.
Publicado: (2019)

A glimpse into the future of systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2022)

Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?
por: Chandrasekar, Thenappan, et al.
Publicado: (2016)

Molecular and cellular characterization of ABCG2 in the prostate
por: Pascal, Laura E, et al.
Publicado: (2007)

Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2018)

Stromal mesenchyme cell genes of the human prostate and bladder
por: Goo, Young Ah, et al.
Publicado: (2005)

Association of Sweet's Syndrome and Systemic Lupus Erythematosus
por: Barton, J. L., et al.
Publicado: (2011)

Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons — California, 2007–2017
por: Gianfrancesco, Milena A., et al.
Publicado: (2021)

The urologic epithelial stem cell database (UESC) – a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladder
por: Pascal, Laura E, et al.
Publicado: (2007)

CD90/THY1 is over-expressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker
por: True, Lawrence D, et al.
Publicado: (2010)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

The Impact of Telemedicine on Rheumatology Care
por: Tang, Wei, et al.
Publicado: (2022)

Study the Expression of CD10 in Prostate Carcinoma and its Correlation with Various Clinicopathological Parameters
por: Singh, Lalit, et al.
Publicado: (2019)

Application of affymetrix array and massively parallel signature sequencing for identification of genes involved in prostate cancer progression
por: Oudes, Asa J, et al.
Publicado: (2005)

Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis
por: Gomez Mendez, Liliana Michelle, et al.
Publicado: (2019)

Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications
por: Wang, Kai, et al.
Publicado: (2014)

Locus-specific gene repositioning in prostate cancer
por: Leshner, Marc, et al.
Publicado: (2016)

The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation
por: Liu, Alvin Y.
Publicado: (2021)

Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells
por: Gheibi, Pantea, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jja0ab1lprj5tqbcn8t81a56b8